Specifically, AURKA inhibitors can cause more ARID1A-deficient cells to enter G2/M arrest and trigger tumor cell apoptosis because the loss of ARID1A can upregulate the expression level of AURKA, which acts as an oncogene that can cause tumor cell overriding cell cycle checkpoints by phosphorylate CDC25 Cat Ser198 via PLK1 and activate CDC25C nuclear translocation leading to tumor cells overriding cell cycle checkpoints, and enhancing cell proliferation, and suppressing apoptotic pathways [188, 189]. Here, PLK1 is linked to neoplasm.